VIR-576
 VIR-576 3D | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| ChemSpider | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C224H322N42O51S2 |
| Molar mass | 4483.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection.[1] This drug is a synthesized variant of a highly specific natural entry inhibitor designated as VIRIP (virus-inhibitory peptide).[2]
The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by Frank Kirchhoff and coworkers.[3] This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG.[4]
Origins and development
[edit]
In 2007,[5] a new natural peptide was discovered in the human organism and was called VIRIP. It is generated from alpha-1-antitrypsin, a protease inhibitor that belongs to the serine family, by matrix metalloproteinases. It was shown that it could interact with the HIV-1 and stop the virus multiplication. In spite of interacting in a highly intensity with gp-41,[2] the VIRIP did not prevent the multiplication of the virus. So, it was decided to increase the efficacy of this molecule creating other ones that could be more powerful. Among these 600 created molecules,[6] there was the VIR-576 which was synthesized using the solid-phase peptide synthesis method. Moreover, another molecule was used to protect the amino groups, the fluorenylmethyloxycarbonyl chloride. The next step was the purification before lyophilizing it with mannitol. Other peptides were made such as the VIR-353 or the VIR-449.[citation needed]
Structure
[edit]
The VIR-576 is a peptide.[7] Consequently, it is a molecule formed by a sequence of amino-acids united by peptide bonds. If we compare both primary structures, it can be seen that the VIR-576 has 2 subunits. Each subunit, monomer is a variant form, a mutant of the VIRIP,[1] differing from four amino acids.
Thus, among the new ones introduced, it is important to emphasize the importance of the cysteine (C) introduced replacing the methionine (M), both being sulfated amino acids, in the stabilization of its structure.[citation needed]
VIR-576 can establish more hydrogen bonds because it has 41 H-bond donors and 56 H-bond acceptors[8] in comparison with the 23 H-bond donors and 30 H-bond acceptors[9] of the VIRIP.Therefore, it's able to form more interactions and react with the gp-41 in a higher intensity than the VIRIP.[citation needed]
Another important interaction that we must underline is the disulfide bond established between both cysteines of the two monomers of the VIR-576 which allows the peptide to have more structural stability in the space in comparison with the VIRIP. Moreover, the ring form that appears in the secondary structure is due to this interaction between both sulfate atoms. Thanks to this disulfide bond, a cystine is formed. This fact allows the union of the subunits during the reaction with the gp41 and also allows them to act simultaneously. Thanks to all this activity and to the dimerization respect to the VIRIP, the VIR-576 is more effective.[10]
Pharmacology
[edit]Mechanism of action
[edit]
VIR-576 belongs to a kind of drugs categorized as antiretroviral, specifically it is an anchoring inhibitor that blocks HIV-1 entry into the host cell. It binds to a concrete hydrophobic fusion peptide called gp41, which is a transmembrane glycoprotein located in the retrovirus HIV-1 envelope.[2] Target cell interacts with the gp41 peptide in order to form a pre-hairpin structure which joins HIV-1 and host cell membranes.[citation needed]
Gp41 is exposed with the assistance of another glycoprotein (gp120) also located in the envelope of the retrovirus.[11] The structural reason is based on the fact that two gp41 combine with other gp120 composing a trimer.[12] Firstly, it interacts with the receptor CD4 of a T4 human cell (also called Th or helper lymphocyte). The fusion causes an increase of concentration of HIV-1 on the target cell’s surface, and that promotes a switch which increases the affinity of gp120 for chemokine receptors that are disposed onto the target cell surface. This interaction produces a conformational change in the glycoprotein gp120 that exposes gp41. This process would be active because VIR-576 does not interferes in this part of it, but when gp41 is exposed, the developed drug VIR-576 would commence its mechanism of action and the inhibition of the fusion would start to take place.[citation needed]
VIR-576 binding to gp41 inhibits the anchoring of the virus and the membrane fusion, and that means that the genetic controlling material of the retrovirus HIV-1 can not be introduced in the T4 lymphocyte. As a result, infection would not be initiated.[citation needed]
Differences from other antiretroviral drugs
[edit]VIR-576 mechanism of action differs from other drugs. Enfuvirtide (also known as T-20), for example, is a fusion inhibitor which binds to a region of the glycoprotein gp41 called HR1 in order to prevent membrane fusion.[13] While enfurtivide inhibits the formation of the hairpin which is able to trigger the membrane fusion, VIR-576 directly blocks the insertion inhibiting the anchorage which is the previous stage of the hairpin formation (because to develop the hairpin it is necessary the fusion and VIR-576 impedes it.[2]
Dosage forms
[edit]VIR-576 is actually under clinical trials (together with Sifurtivide). In 2010, in order to examine the efficacy of the peptide, a short-term monotherapy[2] in HIV-infected patients was executed by a group of researchers. The results were proof of concept that fusion peptide inhibitors suppress viral replication in human patients, and offer prospects for the development of a new class of drugs that prevent virus particles from anchoring to and infecting host cells. The dosage form described below, belongs to the mentioned study.[citation needed]
Once the VIR-576 was chemically synthesized, it followed a purifying method that turned it into a highly pure drug substance, which was dehydrated in 500ml vials. Immediately before its use, the antiretroviral drug was dissolved in a second vial with bicarbonate-buddered saline, so it could be used in infusions.[citation needed]
The doses of VIR-576 were different between the groups of the study, but the highest one (5,0 grams per day) was the one which reduced more the viral load in the plasma.[citation needed]
Advantages
[edit]Compared with other antiretroviral drugs such as Enfuvirtide and Maraviroc, VIR-576’s mechanism has allowed it to being effective against resistant strains.[14] The reason why is so efficient is that gp41 protein can not mute, so, as a result VIR-576 will always be active as a HIV-1 fusion inhibitor.[citation needed]
Even since its discovery, VIRIP was more efficient to prevent HIV’s infection of T4 lymphocyte, independently of the presence of CCR5 receptors or CXCR4, and it was also effective against a large subtypes of HIV-1.[3]
The patients under treatment were carefully monitored, and most of them didn’t show secondary effects. Generally, the effects were temporal and tolerable like constipation, headaches, and fever, but a couple of patients showed allergic reactions and hyperbilirubinemia. The side effects were less severe in the high- dose treatment group and thus were not related to the dosage of VIR- 576. In conclusion, VIR-576 was well tolerated and did not cause major adverse effects.[citation needed]
See also
[edit]References
[edit]- ^ a b Liz Highleyman (2011). "Novel Entry Inhibitor VIR-576 Shows Promise in Early Study". hivandhepatitis.com.
- ^ a b c d e Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Giménez-Gallego G, Hirsch J, Jiménez-Barbero J, Meyer-Olson D, Münch J, Pérez-Castells J, Ständker L, Kirchhoff F, Schmidt RE (December 2010). "Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide". Sci Transl Med. 2 (63): 63re3. doi:10.1126/scitranslmed.3001697. hdl:10261/52876. PMID 21178138. S2CID 24783051.
- ^ a b "El descubrimiento de un inhibidor del VIH en sangre humana apunta a un nuevo tipo de inhibidor de la fusión" [The discovery of an HIV inhibitor in human blood points to a new kind of fusion inhibitor] (in Spanish).
- ^ Kelland K (2010). "VIR-576: Experimental HIV medicine can halt one of the earliest stages of HIV". Reuters.
- ^ Poveda E (2007). "Discovery of VIRIP--a natural HIV entry inhibitor" (PDF). AIDS Rev. 9 (2): 126. PMID 17694679.
- ^ Lic. Aleida Figueroa Silverio (2010). "Diseñan nuevo fármaco capaz de frenar la entrada del VIH en las células" [They design new drug able to slow the entry of HIV into cells] (in Spanish).
- ^ Jefferys R (2011). "Anchors Away: New HIV Entry Inhibitor Study Creates a Splash". Treatment Action Group (TAG).
- ^ "AIDS#: 472841". NIAID database. U.S. National Institute of Allergy and Infectious Diseases.
- ^ "[A20]VIRIP - Compound Summary". PubChem.
- ^ González-Ortega E, Ballana E, Badia R, Clotet B, Esté JA (December 2011). "Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1". Antiviral Res. 92 (3): 479–83. doi:10.1016/j.antiviral.2011.10.010. PMID 22027647.
- ^ O'Brien WA (July 31, 2001). "HIV entry—from molecular insights to specific inhibitors". Medscape HIV/AIDS Conference Coverage. Medscape.
- ^ Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH (November 2008). "Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs". PLOS Pathog. 4 (11): e1000203. doi:10.1371/journal.ppat.1000203. PMC 2577619. PMID 19008954.
- ^ Patel IH, Zhang X, Nieforth K, Salgo M, Buss N (2005). "Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide". Clin Pharmacokinet. 44 (2): 175–86. doi:10.2165/00003088-200544020-00003. PMID 15656696. S2CID 2516685.
- ^ Gonzalez E, Ballana E, Clotet B, Esté JA (August 2011). "Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP)". AIDS. 25 (13): 1557–83. doi:10.1097/QAD.0b013e328348a733. PMID 21572303. S2CID 44666566.